ARA-290

ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the helix-B region of erythropoietin (EPO). It is non-erythropoietic — it does not stimulate red-blood-cell production — and in preclinical research is studied for selective activity at the innate repair receptor, a heteromeric complex of the EPO receptor and the beta-common receptor that mediates tissue protection and inflammation resolution. This separates its studied tissue-protective signalling from EPO's haematopoietic effects. Supplied at >99% HPLC purity for in-vitro research use only.

Native erythropoietin drives red-blood-cell production via the classical EPO receptor homodimer. ARA-290 is derived from EPO's helix-B domain but is engineered to engage only the innate repair receptor (EPOR/beta-common heteromer) rather than the haematopoietic homodimer. In research this means it can be used to study EPO's tissue-protective signalling pathways without the erythropoietic (red-cell-stimulating) activity — a key reason it is of interest as a research tool. Not for human consumption — for research use only.

Add bacteriostatic water to the vial slowly, directing it down the inside wall rather than onto the powder, then swirl gently until fully dissolved. Do not shake or vortex. Storage: Lyophilised — store at −20°C for up to 24 months. Reconstituted — refrigerate at 2–8°C and use within 4 weeks, protected from light. BAC water is available at /products/bac-water-10ml. Not for human consumption — for research use only.

Legal status: ARA-290 is legal to purchase in Australia for legitimate laboratory research purposes. It is not for human consumption, therapeutic, cosmetic, or veterinary use and is not TGA-approved. Purchasers must be 18+ and confirm research-only intent. Quality: each batch is manufactured to a >99% HPLC purity specification under GMP-certified conditions.

Peptide Warehouse Australia stocks ARA-290 10mg and ships nationwide via Australia Post with full tracking. Orders placed before 12PM AEST dispatch the same business day from our Melbourne warehouse; orders after 12PM AEST dispatch the next business day. Standard Post $8.99 (2–6 business days); Express Post $13.99 (1–3 business days); free shipping on all orders over $199 AUD. All orders ship in discreet plain packaging with no external branding. Not for human consumption — for research use only.

ARA-290 (Cibinetide) is studied for selective activity at the innate repair receptor — a heteromeric complex of the EPO receptor and the beta-common receptor — which mediates tissue-protection and inflammation-resolution signalling distinct from EPO's red-cell-stimulating receptor. Not for human consumption — for research use only.

ARA-290 has been examined in preclinical and early clinical research in the context of small-fibre neuropathy and neuropathic pain models, tied to innate-repair-receptor signalling. These are research findings only; the compound is supplied strictly for research. Not for human consumption — for research use only.

Because the innate repair receptor is involved in resolving inflammation, ARA-290 has appeared in research examining inflammatory conditions including sarcoidosis models, focusing on tissue protection and immune modulation. This work is research-only and not TGA-approved. Not for human consumption — for research use only.

ARA-290 is derived from EPO's helix-B domain but engineered to engage only the innate repair receptor, not the classical EPO-receptor homodimer that drives red-cell production. This lets researchers study EPO's tissue-protective signalling without the erythropoietic (red-cell) effect. Not for human consumption — for research use only.

ARA-290 is also known as cibinetide and is sometimes written ARA290. It is a non-erythropoietic, EPO-derived research peptide. For in-vitro research use only.